NCT02057159View on ClinicalTrials.gov

A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

March 9, 2020

Primary Completion Date

March 9, 2023

Study Completion Date

March 9, 2023

Conditions
Secondary Progress Multiple SclerosisMultiple Sclerosis
Interventions
BIOLOGICAL

NeuroVax

TCR peptides in IFA

BIOLOGICAL

IFA Placebo

IFA Placebo

Trial Locations (1)

92129

RECRUITING

CRO, San Diego

Sponsors
All Listed Sponsors
collaborator

cro

AMBIG

lead

Immune Response BioPharma, Inc.

INDUSTRY